Regulatory decisions over the holidays resulted in disappointing news for two drugmakers. Sanofi and Corcept reported surprise rejections from the U.S. FDA for applications filed late in 2025, with Corcept receiving a complete response letter for relacorilant in Cushing’s syndrome. Corcept said it will now prioritize a planned regulatory submission for relacorilant in platinum‑resistant ovarian cancer with a July 2026 PDUFA date. The actions underline ongoing regulatory scrutiny of endocrine and neurology portfolios.